1. Home
  2. COOK vs BMEA Comparison

COOK vs BMEA Comparison

Compare COOK & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

SELL

Current Price

$49.53

Market Cap

134.6M

ML Signal

SELL

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.85

Market Cap

140.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
BMEA
Founded
1985
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.6M
140.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
COOK
BMEA
Price
$49.53
$1.85
Analyst Decision
Hold
Strong Buy
Analyst Count
5
6
Target Price
$53.00
$9.83
AVG Volume (30 Days)
13.8K
2.3M
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
$559,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.87
52 Week High
$86.59
$2.99

Technical Indicators

Market Signals
Indicator
COOK
BMEA
Relative Strength Index (RSI) 35.10 61.74
Support Level $47.15 $1.17
Resistance Level $77.25 $2.03
Average True Range (ATR) 2.41 0.15
MACD 0.12 -0.01
Stochastic Oscillator 14.19 52.44

Price Performance

Historical Comparison
COOK
BMEA

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: